The development, testing and validation of digital image analysis workflows is a complex process that requires a high-level of domain knowledge and technical expertise. There are many variables that can affect the results, including slide scanning platform parameters, approach to algorithm testing and training, analyst training, quality control methods, applying artificial intelligence (AI) and others. To address the variability and challenges, a fully customized approach can be developed based on the research question, clinical stage of development and intended use of the data.
In this webinar, the speakers will address:
Speaker information below.
Dr. Krueger serves as the Vice President of Advanced Pathology Services at Invicro. In his role, Dr. Krueger is responsible for developing new biomarker applications to meet drug development needs, and provides scientific expertise needed to support sponsor-based projects across therapeutic areas. Prior to joining Invicro, Dr. Krueger was Chief Scientific Officer at Flagship Biosciences, Inc., where he led the R&D and Scientific efforts in applying novel quantitative tissue image analysis approaches to immuno-oncology and rare diseases to support drug and companion diagnostic development. Prior to Flagship Biosciences, he served in senior scientific roles in oncology drug development for OSI Pharmaceuticals in Boulder, CO and Pfizer in Andover, MA. Dr. Krueger completed his postdoctoral fellowship at The Scripps Research Institute and The University of California, San Diego after completing his Ph.D. in Cancer Biology at Wayne State University in Detroit, MI.
Dr. Ghasemi is a Senior Imaging Scientist at the department of Advanced Pathology Services at Invicro. He has more than 7 years of research experience in imaging informatics and data analysis developing digital pathology pipelines for drug and biomarker development. Currently, Dr. Ghasemi is leading efforts to develop innovative image analysis applications and workflows across a wide breadth of histopathology projects for both clinical and preclinical studies. Prior to joining Invicro, he worked for three years as an Imaging Scientist on several drug research projects at different preclinical stages at Takeda Pharmaceuticals. Dr. Ghasemi completed his postdoctoral fellowship in mathematical modeling and imaging research at Merrimack Pharmaceuticals in Cambridge, MA. He holds a Ph.D. in Electrical Engineering with a concentration in image & signal processing and computational biology from The University of Texas at San Antonio.